Aramchol - Galmed Pharmaceuticals

Drug Profile

Aramchol - Galmed Pharmaceuticals

Alternative Names: Aramchol

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galmed Medical Research
  • Developer Galmed Medical Research; Galmed Pharmaceuticals; University of California, San Diego
  • Class Bile acids and salts; Cholic acids; Drug conjugates; Eicosanoic acids; Eicosanoids; Fatty acids; Small molecules
  • Mechanism of Action Stearoyl-CoA desaturase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Lipodystrophy

Highest Development Phases

  • Phase II Cholelithiasis; Lipodystrophy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 09 Jan 2017 Galmed Pharmaceuticals completes enrolment in the ARREST phase IIb trial for Non-alcoholic steatohepatitis in USA, Chile, Colombia, Mexico, Peru, France, Germany, Italy, Romania and China
  • 01 Dec 2016 Galmed Pharmaceuticals completes a pharmacokinetic study in healthy volunteers in USA (NCT02803996)
  • 22 Sep 2016 Galmed Pharmaceuticals and University of California at San Diego enter into a clinical trial agreement for a phase I/II trial in Non-alcoholic fatty liver disease (In adolescents)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top